Oral GLP-1, for Type 2 Diabetes

Many experts believe that the future of Type 2 Diabetes treatment lies with the various analogues of GLP-1 (Glucagon-Like Peptide) that are being developed. GLP-1 is a natural peptide hormone involved in controlling blood sugar levels.

Novo Nordisk is using our Eligen® drug delivery technology in combination with its proprietary GLP-1 receptor agonists and insulins. During December 2010, the Company entered into an exclusive Development and License Agreement with Novo Nordisk to develop and commercialize oral formulations of Novo Nordisk's insulins using Emisphere's Eligen® Technology (the "Insulin Agreement").

This was the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial. The Insulin Agreement included $57.5 million in potential product development and sales milestone payments to Emisphere, of which $5 million was paid upon signing, as well as royalties on sales.

This extended partnership with Novo Nordisk has the potential to offer significant new solutions to millions of people with diabetes worldwide and it also serves to futher validate our Eligen® Technology.